Brief: Scynexis Provides Corporate, Commercial And Research And Development Strategy Updates To Expand Market Potential For Its First-In-Class Antifungal

Scynexis

20/10/2022 12:57

Oct 20 (Reuters) - SCYNEXIS Inc  SCYX.O :
    * SCYNEXIS PROVIDES CORPORATE, COMMERCIAL AND RESEARCH AND
DEVELOPMENT STRATEGY UPDATES TO EXPAND MARKET POTENTIAL FOR ITS
FIRST-IN-CLASS ANTIFUNGAL
    * SCYNEXIS INC - ANNOUNCING A NEW STRATEGIC DIRECTION ON
CLINICAL
DEVELOPMENT OF IBREXAFUNGERP, ANTICIPATED FIRST APPROVAL IN
HOSPITAL SETTING IN 2024
    * SCYNEXIS INC - INTENDS TO OUT-LICENSE BREXAFEMME FOR
VULVOVAGINAL CANDIDIASIS
    * SCYNEXIS INC - DURING THIS PROCESS, CO WILL WIND DOWN ITS
PROMOTIONAL ACTIVITIES, WHILE KEEPING BREXAFEMME ON MARKET AND
AVAILABLE TO PATIENTS
    * SCYNEXIS INC - WILL CONCLUDE PARTNERSHIP WITH ITS
CONTRACTED
COMMERCIAL SALES PARTNER, AMPLITY HEALTH, AND WILL UNDERTAKE A
WORKFORCE REDUCTION
    * SCYNEXIS INC - RESULTING RESOURCES WILL BE REDIRECTED TO
HOSPITAL PROGRAM AND WILL EXTEND CASH RUNWAY INTO Q2 2024
    * SCYNEXIS INC - MARCO TAGLIETTI, M.D., PRESIDENT AND CHIEF
EXECUTIVE OFFICER OF SCYNEXIS, WILL RETIRE AS OF DECEMBER 31,
2022
    * SCYNEXIS INC - DAVID ANGULO, M.D., CHIEF MEDICAL OFFICER
SINCE
2015, WILL BECOME PRESIDENT AND CHIEF EXECUTIVE OFFICER,
EFFECTIVE JANUARY 1, 2023
    * SCYNEXIS INC - IVOR MACLEOD WILL JOIN SCYNEXIS AS CHIEF
FINANCIAL OFFICER ON OCTOBER 24

Source text for Eikon:  ID:nGNX62hfjb 
Further company coverage:  SCYX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))